A new method to enhance T cell modification using engineered viruses
A Novel Vector Platform to Actualize T Cell Modification In Vivo
['FUNDING_R21'] · WASHINGTON UNIVERSITY · NIH-10663022
This study is exploring a new way to deliver gene editing tools directly into T cells using specially modified viruses, which could lead to better cancer treatments that are more precise and effective for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10663022 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel vector platform that combines adenoviruses and adeno-associated viruses to improve the delivery of gene editing tools directly into T cells. By using advanced techniques to modify the virus capsids, the researchers aim to enhance the targeting efficiency of these viruses to specific tissues, such as the liver. The approach involves using engineered viral components to facilitate better gene editing outcomes, potentially leading to more effective immunotherapy treatments for cancer. Patients may benefit from this innovative method that aims to improve the precision and effectiveness of T cell modifications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may benefit from enhanced T cell therapies.
Not a fit: Patients with non-malignant conditions or those not eligible for T cell modification therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer patients by improving T cell modification techniques.
How similar studies have performed: Other research has shown promise in using engineered viral vectors for gene delivery, indicating that this approach could be a significant advancement in the field.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CURIEL, DAVID TERRY — WASHINGTON UNIVERSITY
- Study coordinator: CURIEL, DAVID TERRY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer